Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history

Данилов, Д. С.

doi:10.14412/2074-2711-2015-1-66-74

Cited by 4 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Known together as reuptake inhibitors, they prevent the reuptake of one or some neurotransmitters so that the majority of them are present and active in the brain. SSRIs work at the expense of specific inhibition of serotonin reuptake [40]. Some SSRIs as citalopram, escitalopram, sertraline, fluoxetine, and paroxetine are effective for treatment of depressive disorders in most cases of schizophrenia.…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Novitsky

Sousa

Asadullin

et al. 2021

jour

View full text Add to dashboard Cite

The purpose of this review is to analyze approaches to the treatment of depressive and negative disorders in schizophrenia in terms of their level of efficacy and safety. Materials and Methods: A search was conducted for full-text articles published over the last 10 years in PubMed, Springer, Wiley Online Library, Taylor & Francis Online, APA PsycInfo, CORE, Science Direct, and eLIBRARY.RU databases. Several articles published previously to this period were also included into the review due to their high scientific value. Results: Our review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs). However, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance. Negative symptoms of schizophrenia, including those induced by a number of АP, are less amenable to correction by АDs monotherapy, which requires a long period of АPs (on average - 8 weeks), which can be limited in the real life of the patient outside the hospital. Current approaches to the therapy of depressive disorders in patients suffering from schizophrenia vary from country to country. However, most of АDs used in clinical psychiatric practice are widely used in the comorbid state under consideration. Conclusion: The efficacy and safety of АDs of the different classes considered in this review depends on their mechanisms of action, duration of admission, type of АPs taken, and specific clinical situation (acute depressive disorder, major depressive episode, or chronic depressive episode). Most promising in clinical practice are serotonin–norepinephrine reuptake inhibitors (SNRIs) and dual ADs. The use of tricyclic antidepressants (TCAs) is limited due to a higher risk of adverse drug reactions (ADRs). The use of most selective serotonin reuptake inhibitors (SSRIs) is limited due to the risk of aggravation of hallucinations (this risk being higher for patients with visual hallucinations, and lower for those with auditory hallucinations) and\or iatrogenic psychosis. These ADRs may probably occur in patients suffering from schizophrenia due to their ideal "poor metabolizer" pharmacogenetic profile, since most of the drugs considered in this review have hepatic metabolism.

show abstract

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Novitsky

Sousa

Asadullin

et al. 2021

jour

View full text Add to dashboard Cite

show abstract

Executive functions and their role in predicting therapeutic response in patients with depressive disorders

Галкин¹,

Ivanova²,

Бохан³

2021

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Comparative pharmacoepidemiological analysis of the structure of prescribing antidepressants in the treatment of anxiety and depressive disorders

Barylnik¹,

Филиппова²,

Maslova³

et al. 2022

Bulletin of Neurology, Psychiatry and Neurosurgery

View full text Add to dashboard Cite

Introduction. Anxiety-depressive disorders are among the most common psychiatric disorders in the group of borderline conditions, and antidepressants are widely used for their treatment. Around the world, there is an active development of new drugs with thymoanaleptic activity, as well as in-depth study and comparison of the efficacy and safety of existing drugs. Due to this, the approach to psychopharmacotherapy of anxiety-depressive disorders and the very structure of prescribing antidepressants are constantly changing. Thus, the analysis of the structure of prescribing antidepressants, as well as the identification and justification of the changes that this structure inevitably undergoes over time, becomes extremely relevant. Purpose of the study. Conduct a pharmacoepidemiological analysis of the structure of prescribing antidepressants to patients with anxiety-depressive disorders of the neurotic register (F 06.41 — Organic anxiety disorder due to cerebrovascular disease, F 41.0 — Panic disorder (episodic paroxysmal anxiety), F 41.2 — Mixed anxiety and depressive disorder and F 45 — Somatoform disorders according to ICD-10) in two comparable groups of patients treated in the Department of Crisis States of the Clinic of Hematology and Occupational Pathology of the SSMU in 2010–2012 and 2019–2021 respectively. Materials and methods. The volume of antidepressant prescriptions was assessed, taking into account dosages and treatment regimens, using the «Defined Daily Doses» technique in each of the study groups. Differences in the structure of prescribing antidepressants in the study groups were identified and analyzed, as well as the causes and prerequisites for their occurrence were investigated. Results. The conducted comparative pharmacoepidemiological study revealed discrepancies in the structure of antidepressant prescriptions in the 2010–2012 groups. and 2019–2021 Maprotiline was in second place in terms of prevalence in the 2010–2012 group, while in the 2019–2020 group never been appointed. By the end of the decade, the frequency of prescribing clomipramine significantly decreased, which in the 2010–2012 group ranked third in terms of appointments. When comparing groups of 2010–2012 and 2019–2021 it was found that in the first case, the volume of clomipramine prescriptions was almost 6 times higher. There is a trend towards an increase in the volume of prescriptions for almost all drugs of the SSRI group, both individually and for this group as a whole. The structure of prescriptions is significantly influenced by such factors as an in-depth study of the main and side effects of drugs, accessibility for patients and the volume of supplies of individual drugs to the territory of the Russian Federation. Conclusion. Modern pharmacoepidemiological studies make it possible to study in depth the advantages and disadvantages of each specific antidepressant, so that in each clinical case it is possible to choose the most suitable drug or combination thereof. It is necessary to continue and increase the scale of such studies, maintaining their independence from the financing of pharmaceutical companies, as well as to expand the local market for psychopharmacotherapeutic agents so that its limitations do not reduce the effectiveness of the therapy on a large scale.

show abstract

Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history

Cited by 4 publications

References 17 publications

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Executive functions and their role in predicting therapeutic response in patients with depressive disorders

Comparative pharmacoepidemiological analysis of the structure of prescribing antidepressants in the treatment of anxiety and depressive disorders

Contact Info

Product

Resources

About